Register for email alerts and news feeds:
This journal | BMJ Group
rss
Annals of the Rheumatic Diseases 2008;67:438-442; doi:10.1136/ard.2007.083873
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism.

EDITORIALS

Antiphospholipid syndrome dilemmas still to be solved: 2008 status

Yehuda Shoenfeld1, Pier Luigi Meroni2, Ricard Cervera3

1 Department of Medicine "B" and Centre for Autoimmune Diseases, Sheba Medical Centre, Sackler Faculty of Medicine, Tel-Aviv University, Israel
2 Department of Internal Medicine, University of Milan Allergy, Clinical Immunology and Rheumatology Unit, IRCCS, Istituto Auxologico Italiano, Italy
3 Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain

Correspondence to:
Yehuda Shoenfeld, Sheba Medical Center, 52621 Tel-Hashomer, Israel; shoenfel@post.tau.ac.il

Accepted 3 January 2008

The first 150 words of the full text of this article appear below.

Extensive investigation of antiphospholipid syndrome (APS) has improved our knowledge of the disease, but raised new questions. Although the pathogenic role of antiphospholipid antibodies (aPL) is widely accepted, the fact that aPL induces thrombotic events only occasionally suggests the need for a "second hit" to display the thrombogenic effect. Infectious agents are thought to trigger autoantibody production through a molecular mimicry mechanism, but may also induce an inflammatory process that eventually favours clotting. The involvement of complement and cytokines in the pathogenesis further supports the role of inflammation in APS as well as the possibility for new therapeutic approaches. The question of whether other environmental triggers or a genetic individual susceptibility can behave as a second hit is still open. The clinical involvement of different organs and systems poses the question of whether the syndrome should be considered a true systemic autoimmune disease, rather than an acquired autoimmune coagulopathy. A . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Rotar, Z, Rozman, B, de Groot, P., Sanmarco, M, Shoenfeld, Y, Meroni, P., Cervera, R, Pengo, V, Cimaz, R, Avcin, T, Carp, H., Tincani, A (2009). Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome?. Lupus 18: 53-60 [Abstract]  
  • Brandt, J. D. (2008). Finding Risks for Glaucoma. Arch Ophthalmol 126: 1138-1139 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs